Skip to main content
. 2022 Sep 8;42(10):937–970. doi: 10.1002/cac2.12359

FIGURE 4.

FIGURE 4

OS and PFS of patients with unresectable NSCLC after first‐line immunotherapy in phase 3 randomized controlled trials. Abbreviations: ITT, intention‐to‐treat; NR, not reach; NSCLC, non‐small cell lung cancer; OS, overall survival; PD‐L1, programmed death‐ligand 1; PFS, progression‐free survival; #, phase III clinical trials on innovative immune checkpoint inhibitors from China.